

Luisa Gomez NUTR 7200 Probiotics

1. Has the definition of probiotic changed since 2001?

According to Consensus Statements, in 2001 an Expert Consultation of international scientist working on behalf of the Food and Agriculture Organization of the United Nations (FAO) met to discuss probiotics. They reworked the definition of probiotics to "live microorganisms which when administered in adequate amounts confer a health benefit on the host." (p.1). This specific definition has been used for probiotics since then.

2. What are the benefits of probiotics?

Two common benefits associated with probiotics: supporting a healthy digestive tract and a healthy immune system. (Consensus Statement p.3) Other benefits of probiotics is they help create a more favorable gut environment, gut immune response, and intestinal homeostasis, prevention and treatment of diarrhea, improvement of faecal properties and microbiota, treatment of irritable bowel syndrome, inflammatory bowel disease and constipation. (International Journal of Environmental Research and Public Health p. 4752).

Health benefits have mainly been linked to specific probiotic strains: *Lactobacillus*, *Bifidobacterium*, *Saccharomyces*, *Enterococcus*, *Streptococcus*, *Pediococcus*, *Leuconostoc*, *Bacillus*, *Escherichia coli*. (International Journal of Enveronimental Research and Public Health p. 4745).

3. Are there risks to taking probiotics?

Although probiotics have an excellent overall safety record, they should be used with caution in certain patient groups—particularly neonates born prematurely or with immune deficiency. It is demonstrated that the use of certain probiotics on immunocompromised patients with leaky gut has resulted in infections, sepsis, bacteraemia, and fungemia (International Journal of Enveronimental Research and Public Health p. 4745). The properties of different probiotic species vary and can be strain-specific. Therefore, the effects of one probiotic strain should not be generalized to others without confirmation in separate studies.

4. How do you determine which probiotic(s) to recommend to patients/clients?

Although most probiotics are regarded as safe and beneficial for healthy individuals, caution needs to be taken when selecting and recommending probiotics to patients. It is very important to be careful with the science and not to oversell it ((International Journal of Enveronimental Research and Public Health p. 4756). Many products currently do not go through pre-market approvals and their efficiency is not well established. Therefore when determining which probiotic to recommend to patients various factors need to be considered:

1. For what conditions does the patient need probiotics? Is it for chronic diarrhea, chronic constipation, abdominal pain, etc.?

- 2. Is the patient healthy or suffering from any disease? Special consideration and caution needs to be taken with immunocompromised patients, the elderly, and children.
- 3. Paying close attention to the probiotic label. Does the probiotic meet all the criteria to be considered a probiotic (according to its definition)?
- 5. Look for your name on the table below and the corresponding probiotic product. Try to locate a study about the probiotic (s) in the product. Provide a brief synopsis of the study.

"GoodBelly probiotic drinks contain live and active cultures of the probiotic strain, Lactobacillus plantarum 299v (LP299V®). This particular strain was chosen out of many, due to the 16 well-documented research trials that indicate their ability to promote healthy digestion.* Additionally, these trials GoodBelly probiotic drinks contain live and active cultures of the probiotic strain, Lactobacillus plantarum 299v (LP299V®). This particular strain was chosen out of many, due to the 16 well-documented research trials that indicate their ability to promote healthy digestion.* Additionally, these trials substantiate that LP299V® has a superior ability to survive the stomach's harsh acidic environment in order to inhabit the intestine. LP299V® has been used by millions of people safely for almost two decades. LP299V® was initially developed for use by gastroenterologists in Sweden to help their patients recover from surgery."

www.goodbelly.com

Clinical trial: Lactobacillus plantarum 299v (DSM 9843)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419998/

In this specific case study, *Lactobacillus plantarum 299v*, which is found in Good Belly products, was studied to assess the symptomatic efficacy for the relief of abdominal symptoms in irritable bowel syndrome (IBS) patients. A double blind, placebo-controlled, parallel designed study was used on two hundred and fourteen IBS patients. The patients were randomized to daily receive either one capsule of *L. plantarum* 299v (DSM 9843) or placebo for four weeks. Symptoms associated with IBS were assessed weekly on a visual analogue scale. After four weeks, both pain severity and daily frequency were lower with *L. plantarum* 299v (DSM 9843) than with placebo. Patients scored *L. plantarum* 299v (DSM 9843) 78.1 % symptomatic effect as excellent or good while only 8.1 % for placebo.

Jomes

attached

NUTR 7200 Parenteral Problems

Parentei	ral P	roble	ems:
L al cilici	CALL	IODI	CITIO.

mass/volume

1. Calculate the final concentration for the following formulas. Each is worth 3 points.

a. 280 grams CHO, 85 grams protein and 45 grams of fat. The total volume is 2100 mL

13.3% Dextrose, 4.0% AA, 2.1% Fat at BBML/m

b. 225 grams CHO and 60 grams of protein. Total volume is 1500 mL.

15% Dextrose, 4% AA 103 mL/m

2. Calculate the grams of CHO, protein, and fat and total calories for the following solutions. Each is worth 5 points.

a. 3: 1 parenteral solution that is 16% dextrose, 5.8 % amino acid and 2.1 % fat. The rate of infusion is 84 mL/hr.

3229 duxtrose 1179 AA 429 Fat 1983 Keal total

b. 2:1 solution: 4.8% amino acid and 20% dextrose at 75 ml/hr; 200 ml

30% lipid emulsion

30% lipid emulsion

30% lipid emulsion

3200 dextrose

3. The pharmacy carries substrates in bulk. How much of a 70% dextrose solution, 15% amino acid solution, and a 30% fat solution would be needed for the following formulas? (4 points each)

a/ 320 grams CHO, 135 grams protein and 55 grams of fat. The total

volume is 2400 mL (3:1 solution)

183 mL Fat, 457 mL dex tyose

5100 mL AA 1 W 64 mL per hour

b. 240 grams CHO and 65 grams of protein. Total volume for CHO

and AA is 1800 mL. Provide 40 grams fat (2:1 solution)

343 ml dextrose + 433 ml AA = 776 + 924 ml H20 (100ml electrolytes)

133 ml fat)

1640 ml SOLUTION

TODMI vy act cr

= 1300 mil

3:1 9.9% Dextrose @ 100mL/hr	
30°10	
 Determine 2:1 and 3:1 solutions for a patient that requires 25 kcal/kg and 1.2-1.5 g protein/kg. The patient weighs 72 kg. (11 points) 	
2:1 4.5% AA, 11.10 Dextrose @ 92 ml/hour	
 Patient in # 4 is placed on a fluid restriction – no more than 1600 ml per day. What is the new final concentration? (4 points) 	
2:1 6.25.10 AA, 15% Dextrose a 67mL/hr 30% Liquid emulsion a 8.2mL/hr	
6. Calculate the osmolarity for the following formulas. (Which one can be	
1 050h AA 1 30% Fat	
2:11 perenteral colution that is 160/ devtroes 5.20/ amino said and	
5.3 × 100= 630 = 1300 100 / L	
a. 3) I parenteral solution that is 10% dextrose, 5.5% animo acid and 2% fat. 2% fat. 5.3 × 100 = 530 (2900 so) (2900	
7 × 50 = 350 = 10 clude 70-100 moms of	00
7. How mg CHO is a patient receiving per kg/min from the following formula: Formula: 3:1 parenteral solution 14% dextrose, 5.5 % AA, 1.9 % fat @ 84	, Long
b. 2:1 solution: 5% amino acid and 7% dextrose The property of the property o	
May be too low. (3-5mg/kg/min) Patient 15 receiving 2.8 mg cho which May be too low. (3-5mg/kg/min) Patient with become hypoglycemic	
8. A patient requires 140 grams of protein/day. What is the minimum volume	
the parenteral solution can be considering the stability range for protein?	
5 stability 20-609 (central)	
Protein Stability 20-409 (peripheral	
(-1-0)-(50)-1100d	
(xme)-(62)=1409 - would flood =7000ml the patient	
= 7000 mx	
(x, x, y,	
(xme) (.06) = 140g / minimum	
= 2333 ml minimum	

CHO: 280 g / 2100 ml × 100 = 13.3% dextrose ro: 85g/2100 mlx 100= 4.0°/. AA Fat: 459/2100 ml x100 = 2.10/0 Fat 2100 ml = 87.5 WD 88 ml/m 24 hrs/d 100 B. 225 g / 1500 ml × 100 = 15% dextrose 2HO: 200: 60g/1500mL × 100 = 4010 AA 1500ml (1)= , 62.5 WT 63 m 24 hrslda C J m CO110% dex trose 5.8% AA Fat 2010/0 = X 1000ml 2016 ml 1179 AA 5.8 2016mL mooc

16	= X X = 3229 dextrose
1000 ml	1
	LANGER TO LA COLLEGIONE
Total	calories
	TO THE STATE OF TH
	322g x 3-4 Kcalg = 1094.8 Kcal
	1179 × 4 Kcal/9= 468 Kcal
	42g × 10 Kcal/g = 420 Kcal
	1982.8 Kcal
a ližtal si i	total
(2 b)	4.8%AA 75m1/hr
	200% dextrose 1800m1/day
200m1-	20% upid emulsion
	360
20	= $x = 320$ g olextrose
1000 mL	2
	1800
4.8	= X X AA
1000mL	N609 800
	200ml - 400 Kcal = (400 Liek
2 Coal	× 200 ml = 10 Kcal/g - 109 Upk
320g 1x	3.4 = (1088 Kcal/9)
340	THE DX
- Na >	4 ccalg: 308 kcalg
4 G	100
Tota	cal = 1796 Kcal

a a

	- 14 T	ρ α	.:	4)
				1
3)	70°10 de	xtrose	3209	CHO
1126	1500 Ar	nino acid	1359	Protein
341	30% Fo	ct	55g	Fat
	135 201	£ - 2 - 3	TV: 240	DOML
30%	Fat			LANGE
559	Fat			
J	wall a gradi	exise e K	* × ^}	1001
30g	= .559	X = 18	33 m L X 1	l i sont
100ml	×		= (-9	
	tail	Jan 38: X	- 2,1%-	30
2400	Mr		. * X	1.00
183	my	\sim	\wedge	
	22/17/10	L AA HO	HODITOR	118001
			55	
70%	dextrose			
3209	CHO		7	
		4		
70 -	MARRO	X=H5	mont dext	105e
100ml	XIV	4 (1/1)	- 070	
		1) /	1 -	
15g =	1359	X = 900	2 and	
100	×	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
			1,77	
	1540 mL	total	24 hrs =	64 ml
151	10 m L + 10	20 ml electro	24 hrs =	per hour
,		- 1640ml =		
			760 ml Water	1

TV. 1800ml

		-
	(2:1 solution)	
(3b)	2409 C+10 - 70% dextrose	(è
	1 659 protein - 15°6 AA	
	T 10 1 10 10 10 10 10 10 10 10 10 10 10 1	
70g	= 240g x = 343 ml dex-	mose
100mL	X	4135
	TCT	202
. 45g	= 65g X = 433 ml AA	
100ml	X mai - X gra	505
	<u> </u>	Lucat.
_30g	= 409 X= 133 ml Fat	
TWOOT		20- 6- B
		81
1800	[776+100] = (924 water)	
	SC CAT ASSO	
	QHQ	22203
3.4	CA) (AA) Dan.	
particular particular and the second of second seco	1 de Marie	20, 721
	\ 0 \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
	V V V V V V V V V V V V V V V V V V V	= 0.CL
		001
AUG T		e d'Er
	La reconstruction of the second secon	
	137 /	1100

30% Lipid emusion 45% carbs

	2:1 / 45% carbs
	25 KCal/Kg (1/4) 72 Kg
(4)	
	1.2-1.5g protein/Kg 1800 Kcal /86.4-108g protein
1800 Ka	al +0+al. 8 (100g)-7 400 k cal
	cal Pro V 2160-2520
1400	=(2400m1)
	16cal CHO 810kcal = 46% keal 2388 cHO
	590 Kcal Fat Emulsion 2008.
	The state of the s
3 Kca	/m1 (30°/0)
	370 real = 111 ml give us 100c
<u> </u>	3 Kcal /ml
	al (total volume)
	1. 21.81.6
-1977	2203 mt= (CHO+AA)
4,00	2205 160.0
100 = 1	Pro) x 100 = 4.5 % AA
100 g (
220311	
(.45)	(1800) = 810 Kcal = 3.4 Kcalg = 2389 CHO
	CHO
2389 (CHO) x 100 = 110/0 Dextrose /
	03mL

Rates 92 ml/hour CHO+AA emulsion Billioal = 4696 les 2400 ML 2389 x 100 = 2400m Hoone hrs

€°		
	5) Fluid restriction - 1600 milde	ay
3:1		
100	ome × 100 = 6.25°/0 AA) quel ome state	<i>a</i> :
160	one state	, dit
	CON ENDING - ON	
238	g x 100= 15% dextrose	1
1600		1
	70 12 25 1 × 5 X	ν
.160	onl = 47 ml/hour	
	l hr	
	277 - Y - Les + D - R - B - E	
2:1	JUN de 1001 >	
	Ibboml	
-	197 mL	(τ)
	1403 ml TV someth sight	
1000	x 100 = 7.1 0/0 AA Ha	do it
***	must be some	fulnus
. 100		\
139	9 x100= 1570/0 dextrose) rud
238		to b
1403		Sut
1 3	103 = 58/ml/hour	volune
	24	Soyan
		can
, ii.	197 = 8.2 mi/hour	1
		AAIDEKE.
<u> </u>	_ 24	NA / Durlose
		000000

ü		
6		
<u></u>	16°/0 × 50 = 800 > 1330 mom	4
	03 5% 100 = 530	
(t.)	NO-exceeds 900	
	NO-exceeds 900	
	BOULDS I'M BOUNDED	
	, b	rs 1
	(5×100=500	
	7×50-350 10 10 10000	1
	850	
	+ electrolytes	
L	< 900 so NO	80
$\widehat{(7)}$	3:1 70Kg	
	14º/o dextrose a 84 mil/hr	
	5,0 % AA	31
8 mm	1.90/0 Fat 2016 my day	
149 =	X = 282 g dextrose	
100	2016	S-1
Sut		
5.5 =	X X=1111 q AA	
100	2716	
~~55		
1.97=	x x = 389 Fax	
1001/40	2016	
Knowly		-
70 K	9 x (x) × 1440 / 1000 = 282	
	50 X = 187000 - (0 8)	

er e a la B